Production (Stage)
Alnylam Pharmaceuticals, Inc.
ALNY
$314.94
-$7.70-2.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.78% | 36.82% | 34.83% | 93.14% | 68.82% |
| Total Depreciation and Amortization | 9.87% | -17.30% | -52.79% | -55.04% | -54.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.91% | -1.55% | -1.72% | -8.54% | -10.73% |
| Change in Net Operating Assets | -986.75% | -451.45% | -659.56% | -158.15% | 156.60% |
| Cash from Operations | -123.85% | -107.98% | 2,766.45% | 178.75% | 135.25% |
| Capital Expenditure | 50.61% | 44.90% | 40.92% | 21.43% | 9.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 135.59% | 69.88% | -58.08% | -247.58% | -186.33% |
| Cash from Investing | 119.69% | 65.26% | -29.28% | -420.16% | -236.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 149.30% | 105.44% | 71.72% | -28.91% | -52.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -172.20% | -135.64% | -79.76% | -20.98% | -12.69% |
| Cash from Financing | 99.99% | 70.89% | 54.01% | -49.42% | -64.62% |
| Foreign Exchange rate Adjustments | 252.99% | -338.44% | 547.84% | -253.21% | -89.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,174.45% | 386.50% | 267.47% | 278.42% | -92.54% |